To Investigate the Role of Gut Microbiome in ADT Related Metabolic Changes in Prostate Cancer Patients
1 other identifier
observational
50
1 country
1
Brief Summary
Prostate cancer is the second most common cancer in male cancer globally and ranked third in Hong Kong. While androgen deprivation therapy (ADT) is the backbone treatment for advanced prostate cancer, it could lead to obesity, metabolic syndrome and increased cardiovascular mortality. Previous studies showed that ADT patients have different gut microbiome compared to non-ADT patients and the gut microbiome might be related to the metabolic changes. However, the underlying mechanism of these metabolic complications is still not fully understood. This study aims to investigate the relationship and related mechanism between the changes in gut microbiomes and ADT-related metabolic change in prostate cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 23, 2020
CompletedFirst Posted
Study publicly available on registry
December 29, 2020
CompletedStudy Start
First participant enrolled
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 6, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 26, 2023
CompletedJanuary 5, 2024
January 1, 2024
1.9 years
December 23, 2020
January 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
To assess the changes in gut microbiota in prostate cancer patients after initiation of androgen deprivation therapy (ADT)
Gut microbiome related metabolites will be measured by ELISA and mass spectrometry.
Baseline, Month 3, Month 6
Eligibility Criteria
Patients diagnosed with prostate cancer and is going to receive ADT treatment will be recruited.
You may qualify if:
- Male subject with age 45 or above
- Histological diagnosis of prostate cancer (acinar type)
- Clinically decided for androgen deprivation therapy (ADT) as treatment for prostate cancer
You may not qualify if:
- History of diabetes
- Patients that have other active treatment for prostate cancer or other cancers (except ADT)
- Patients received treatment, either surgical or medical, that could lead to decrease in serum testosterone prior to commencement of ADT
- Patients will be started on other treatments, including chemotherapy, new generation of androgen-receptor targeted agents, radiotherapy etc, within 6 months of the commencement of ADT.
- Subject with recent antibiotics usage within 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prince of Wales Hospital
Shatin, Hong Kong
Related Publications (27)
Chan SY, Ng CF, Lee KW, Yee CH, Chiu PK, Teoh JY, Hou SS. Differences in cancer characteristics of Chinese patients with prostate cancer who present with different symptoms. Hong Kong Med J. 2017 Feb;23(1):6-12. doi: 10.12809/hkmj164875. Epub 2016 Dec 9.
PMID: 27932742BACKGROUNDDao MC, Clement K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur J Intern Med. 2018 Feb;48:18-24. doi: 10.1016/j.ejim.2017.10.005. Epub 2017 Oct 27.
PMID: 29110901BACKGROUNDWong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF, Sung JJ. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016 Nov;70(5):862-874. doi: 10.1016/j.eururo.2016.05.043. Epub 2016 Jun 8.
PMID: 27289567BACKGROUNDSaylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb;8(2):211-23. doi: 10.6004/jnccn.2010.0014.
PMID: 20141678BACKGROUNDTeoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int. 2015 Sep;116(3):382-7. doi: 10.1111/bju.12967. Epub 2015 Mar 7.
PMID: 25327618BACKGROUNDTeoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol. 2015 May;45(5):483-7. doi: 10.1093/jjco/hyv025. Epub 2015 Feb 26.
PMID: 25724216BACKGROUNDTeoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF. Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population. J Diabetes. 2015 Sep;7(5):672-80. doi: 10.1111/1753-0407.12226. Epub 2014 Dec 22.
PMID: 25266491BACKGROUNDWong SH, Kwong TNY, Wu CY, Yu J. Clinical applications of gut microbiota in cancer biology. Semin Cancer Biol. 2019 Apr;55:28-36. doi: 10.1016/j.semcancer.2018.05.003. Epub 2018 May 18.
PMID: 29782923BACKGROUNDLi JKM, Chiu PKF, Ng CF. The impact of microbiome in urological diseases: a systematic review. Int Urol Nephrol. 2019 Oct;51(10):1677-1697. doi: 10.1007/s11255-019-02225-y. Epub 2019 Jul 12.
PMID: 31301004BACKGROUNDLey RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec 21;444(7122):1022-3. doi: 10.1038/4441022a.
PMID: 17183309BACKGROUNDDabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019 Oct 1;129(10):4050-4057. doi: 10.1172/JCI129194.
PMID: 31573550BACKGROUNDBoutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016 May;124:11-20. doi: 10.1016/j.biochi.2015.06.020. Epub 2015 Jun 29.
PMID: 26133659BACKGROUNDden Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. doi: 10.1194/jlr.R036012. Epub 2013 Jul 2.
PMID: 23821742BACKGROUNDNeuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015 Jul;39(4):509-21. doi: 10.1093/femsre/fuu010. Epub 2015 Feb 19.
PMID: 25701044BACKGROUNDSantos-Marcos JA, Rangel-Zuniga OA, Jimenez-Lucena R, Quintana-Navarro GM, Garcia-Carpintero S, Malagon MM, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018 Oct;116:43-53. doi: 10.1016/j.maturitas.2018.07.008. Epub 2018 Jul 19.
PMID: 30244778BACKGROUNDZhao H, Chen J, Li X, Sun Q, Qin P, Wang Q. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota. FEBS Lett. 2019 Sep;593(18):2655-2664. doi: 10.1002/1873-3468.13527. Epub 2019 Jul 17.
PMID: 31273779BACKGROUNDHarada N, Hanaoka R, Horiuchi H, Kitakaze T, Mitani T, Inui H, Yamaji R. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci Rep. 2016 Mar 10;6:23001. doi: 10.1038/srep23001.
PMID: 26961573BACKGROUNDGao W, Wu D, Wang Y, Wang Z, Zou C, Dai Y, Ng CF, Teoh JY, Chan FL. Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. Stem Cell Res Ther. 2018 Sep 26;9(1):243. doi: 10.1186/s13287-018-0987-x.
PMID: 30257704BACKGROUNDTsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF, Wong KL. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS One. 2016 Sep 6;11(9):e0162217. doi: 10.1371/journal.pone.0162217. eCollection 2016.
PMID: 27598335BACKGROUNDTeoh JY, Ng CF. Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol. 2016 Sep;48(9):1429-35. doi: 10.1007/s11255-016-1337-5. Epub 2016 Jun 2.
PMID: 27256399BACKGROUNDCheung MK, Lam WY, Fung WY, Law PT, Au CH, Nong W, Kam KM, Kwan HS, Tsui SK. Sputum microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing. PLoS One. 2013;8(1):e54574. doi: 10.1371/journal.pone.0054574. Epub 2013 Jan 24.
PMID: 23365674BACKGROUNDHui AW, Lau HW, Chan TH, Tsui SK. The human microbiota: a new direction in the investigation of thoracic diseases. J Thorac Dis. 2013 Aug;5 Suppl 2(Suppl 2):S127-31. doi: 10.3978/j.issn.2072-1439.2013.07.41.
PMID: 23977433BACKGROUNDLiu Y, Wong KK, Ko EY, Chen X, Huang J, Tsui SK, Li TC, Chim SS. Systematic Comparison of Bacterial Colonization of Endometrial Tissue and Fluid Samples in Recurrent Miscarriage Patients: Implications for Future Endometrial Microbiome Studies. Clin Chem. 2018 Dec;64(12):1743-1752. doi: 10.1373/clinchem.2018.289306. Epub 2018 Sep 20.
PMID: 30237148BACKGROUNDChan CWH, Leung TF, Choi KC, Tsui SKW, Chan JYW. Effects of gut microbiome and environment on the development of eczema in Chinese infants. Medicine (Baltimore). 2020 May 22;99(21):e20327. doi: 10.1097/MD.0000000000020327.
PMID: 32481318BACKGROUNDWong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704. doi: 10.1038/s41575-019-0209-8. Epub 2019 Sep 25.
PMID: 31554963BACKGROUNDYu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng AS, Wong VW, Chan FK, Xu X, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brunner N, Kristiansen K, Arumugam M, Sung JJ, Wang J. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800. Epub 2015 Sep 25.
PMID: 26408641BACKGROUNDNg CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep. 2020 Oct 22;10(1):18060. doi: 10.1038/s41598-020-75139-w.
PMID: 33093594BACKGROUND
Related Links
Biospecimen
Total bacterial DNA will be extracted from fecal samples by using the bead-beating method with Qiagen QIAamp PowerFecal Pro DNA kit. The extracted DNA will be quantified by Nanodrop for polymerase chain reaction (PCR)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chi Fai NG, MD
Chinese University of Hong Kong
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 23, 2020
First Posted
December 29, 2020
Study Start
January 14, 2021
Primary Completion
December 6, 2022
Study Completion
September 26, 2023
Last Updated
January 5, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share